Key points

• The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in PV patients.

• AOP2014 induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.

• Click here for the complete article

• Details on the clinical trial at clinicaltrials.gov

---

Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

---

PV Reporter interviewed Dr Heinz Gisslinger at ASH 2014

[contentcards url=”http://www.pvreporter.com/dr-heinz-gisslinger-enlightens-us-treating-mpns-interferon-30-years/” target=”_blank”]